First humans receive experimental Graves' disease treatment
NCT ID NCT07305818
Summary
This is the first human study testing a new drug called MER511 for Graves' disease, an autoimmune condition affecting the thyroid. Researchers will give the drug to 100 adults with Graves' disease to check for side effects and see how their bodies process it. The study will test different doses given as injections under the skin or into a vein to determine what's safe for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site # 1101
RECRUITINGHollywood, Florida, 33024, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site # 1102
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site # 1103
RECRUITINGPhoenix, Arizona, 85053, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site # 1104
RECRUITINGColumbus, Ohio, 43203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site # 1105
RECRUITINGWebster, Texas, 77598, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site # 1108
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.